Genomic instability of Jurkat clone E6-1 T-cell lines affect gene expression and function: implications for T-cell researchers
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1098022 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Jurkat clone E6-1 is a human T-cell line derived from a paediatric case of acute leukaemia, and is frequently employed as a model T-cell for immunology research. In this study, we characterised genomic, transcriptomic, and functional features of Jurkat clone E6-1 cells stored in three different laboratories, and compared these to Jurkat E6-1 cells from the ATCC. Jurkat clone E6-1 populations were first karyotyped, which results showing marked cytogenomic heterogeneity between cell line. These results were confirmed through chromosomal microarray analysis. Whole exome sequencing was then conducted on each cell line, and revealed distinct mutational profiles between populations. Mutational differences between Jurkat clone E6-1 populations detected by cytogenomic approaches and whole exome sequencing led to divergent transcriptomic profiles identified by bulk RNA sequencing, which, in turn, impacted cellular phenotype and function shown by flow cytometry and multiplex cytokine bead array data. Overall, we found substantial genomic heterogeneity between and within Jurkat clone E6-1 cells, resulting in significant differences in gene expression and function. This research highlights the extreme genomic instability of Jurkat clone E6-1 cells, the importance of monitoring cell passage number and procuring fresh cell line stocks, and the value of multi-omic approaches to characterise cell lines to improve the accuracy, reproducibility, and translatability of research.
2025-04-08 | GSE263543 | GEO
Project description:RAD21 ChIA-PET in human Jurkat clone E61 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf
2019-03-03 | GSE127028 | GEO
Project description:FIP-fve, a fungal fruiting body protein from Flammulina velutipes, has potential immunomodulatory properties. Here, we investigated the immunomodulation mechanism of FIP-fve in Jurkat E6-1 cells by conducting cell viability assay and IL-2 release assay. Kinase inhibitors experiment and proteomics analysis were also involved in the mechanism study. It was found that FIP-fve stimulated cell proliferation and enhanced IL-2 secretion in a dose-dependent manner in Jurkat E6-1 cells. Unbiased high-throughput proteomics analysis showed that 4 T cell immune activation markers including ZAP-70, CD69, CD82 and KIF23 were upregulated in response to FIP-fve treatment. Further pathway analysis indicated that MAP2K3/p38 pathway related proteins including MAP2K, p38, ELK, AATF, FOS, and JUN-B were unregulated. In addition, losmapimod (p38 inhibitor) and gossypetin (MAP2K3 inhibitor) inhibited FIP-fve enhanced cell proliferation and IL-2 release in Jurkat E6-1 cells. Our results demonstrate that FIP-fve stimulates cell proliferation and enhances IL-2 secretion through MAP2K3/ p38α activation.
2022-06-09 | PXD032302 | Pride
Project description:Comparison of resting Jurkat/wt vs multiresistant Jurkat/A4 clone
2007-01-09 | E-MEXP-530 | biostudies-arrayexpress
Project description:We used microarray profiling in Jurkat cells to uncover TAL1 dependent genes in a leukemic context. Clonal Jurkat lines expressing a Doxycycline (Dox) -inducible shRNA against TAL1 coding sequence were generated. A clone in which Dox treatment led to 80% decrease of TAL1 mRNA was chosen.
2010-12-14 | E-GEOD-20544 | biostudies-arrayexpress
Project description:Phosphorylation is a reversible post-translational modification, playing a vital role in protein function. In T cells, protein phosphorylation is the key mechanism regulating T cell receptor – driven signaling pathways. In order to gain insights into the phosphoproteome evolution of T cell activation, we performed a large-scale quantitative phosphoproteomics study of Jurkat E6.1 (wild type) and Jurkat gamma1 (Phospholipase gamma1 null) cell clones upon costimulation with anti-CD3 and anti-CD28 antibodies at times ranging from 15 min to as long as 120 min. In total, we identified 5585 phosphopeptides belonging to 2008 phosphoproteins from both cell clones. We detected 130 and 114 novel phosphopeptides in Jurkat E6.1 and Jurkat gamma1 clones, respectively. A significantly lower number of proteins containing regulated phosphorylation sites were identified in Jurkat gamma1 in comparison to Jurkat E6.1, reflecting the vital role of Phospholipase gamma1 in T cell signaling. Several new phosphorylation sites from lymphocyte-specific protein tyrosine kinase (LCK) were identified. Of these, Serine-121 showed significant changes in JE6.1 while only small changes in the Jgamma1 clone.
2015-11-10 | PXD002871 | Pride
Project description:RNA-seq on Jurkat greater than 200bp polyA+ For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf
2017-02-03 | GSE93435 | GEO
Project description:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be a potent inducer of apoptosis in various cancer cell lines and primary cancer cells. However, in clinical trials administration of recombinant TRAIL or TRAIL death receptor agonists did not show sufficient efficacy for treatment of tested malignant disorders compared to standard chemotherapy. Acquired resistance of cancer cells to TRAIL and to other “death receptor” ligands may explain not only the inability of TRAIL and TRAIL “death receptor” agonists to achieve the clearance of cancer cells in vivo but also the escape of cancer cells from immune cell – mediated killing. Selective pressure of TRAIL on TRAIL-sensitive Jurkat T-lymphoblastic leukemia cells provided several TRAIL resistant Jurkat cell line clones (TR1, TR2, TR3). We showed that acquired TRAIL resistance was associated with complex disruption of both extrinsic and intrinsic apoptotic pathways manifested by acquired multi-drug resistant phenotype of TR1, TR2, and TR3 clones. To identify changes associated with TRAIL resistance of Jurkat cells we performed genome-wide gene expression analysis of TRAIL-resistant clones (TR) and compared to WT Jurkat cells. We identified significantly increased expression (1.33-fold change with adjusted p < 0.05) of 73 genes in TR1 clone, 53 genes in TR2 clone and 8 genes in TR3 clone, and significant decrease in expression (0.75-fold change with adjusted p < 0.05) of 174 genes in TR1 clone, 36 genes in TR2 clone and 28 genes in TR3 clone. There was an overlap of only 2 significantly overexpressed (midkine / MDK and zinc finger and BTB domain containing 16 gene / ZBTB16 / PLZF) and 4 downregulated genes (YAP1, IGJ, EIF1AY, RPS4Y1) in all three TR clones.
2016-06-15 | GSE38743 | GEO